Juan Fernando García García-rekin lankidetzan egindako argitalpenak (6)

2020

  1. Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era

    European Journal of Haematology, Vol. 104, Núm. 5, pp. 400-408

2018

  1. Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm

    British Journal of Haematology, Vol. 182, Núm. 4, pp. 534-541

2017

  1. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β2-microglobulin yields a more accurate GELTAMO-IPI

    British Journal of Haematology, Vol. 176, Núm. 6, pp. 918-928

2013

  1. Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas

    Blood Cancer Journal, Vol. 3, Núm. 4

2012

  1. Expression of COX-2 on reed-sternberg cells is an independent unfavorable prognostic factor in Hodgkin lymphoma treated with ABVD

    Blood, Vol. 119, Núm. 25, pp. 6072-6079

2010

  1. Amolecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma

    Blood, Vol. 116, Núm. 8